Algorae Pharmaceuticals Ltd (asx:1AI) Share Price

Company Profile

Business description
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Contact
525 Collins Street
Level 23, Rialto South Tower
MelbourneVIC3000
AUS
T: +61 422180317
https://www.algoraepharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
48

Recommended

Expense guidance changes short-term earnings but not long-term fundamentals.

Roy Van Keulen | 28 January 2026

Read the latest take from our analysts.

Simonelle Mody | 28 January 2026

From cloud computing growth to AI monetization, here’s what we’re looking for in Alphabet’s upcoming earnings report.

Malik Ahmed Khan, CFA | 28 January 2026

Index	Last price	Change	% Change
All Ordinaries	9,236.90	6.40	-0.07%
CAC 40	8,066.68	86.14	-1.06%
DAX 40	24,822.79	71.65	-0.29%
Dow JONES (US)	49,015.60	12.19	0.02%
FTSE 100	10,154.43	53.37	-0.52%
HKSE	27,957.91	131.00	0.47%
NASDAQ	23,857.45	40.35	0.17%
Nikkei 225	53,469.52	110.81	0.21%
NZX 50 Index	13,348.61	64.26	-0.48%
S&P 500	6,978.03	0.57	-0.01%
S&P/ASX 200	8,927.50	4.30	0.05%
SSE Composite Index	4,159.33	8.10	0.20%